1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Chemotherapy Induced Neutropenia - Pipeline Review, H1 2016

Chemotherapy Induced Neutropenia - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 104 pages

Chemotherapy Induced Neutropenia - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Chemotherapy Induced Neutropenia - Pipeline Review, H1 2016’, provides an overview of the Chemotherapy Induced Neutropenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia
- The report reviews pipeline therapeutics for Chemotherapy Induced Neutropenia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Chemotherapy Induced Neutropenia therapeutics and enlists all their major and minor projects
- The report assesses Chemotherapy Induced Neutropenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Neutropenia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Chemotherapy Induced Neutropenia - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Chemotherapy Induced Neutropenia Overview 10
Therapeutics Development 11
Pipeline Products for Chemotherapy Induced Neutropenia - Overview 11
Pipeline Products for Chemotherapy Induced Neutropenia - Comparative Analysis 12
Chemotherapy Induced Neutropenia - Therapeutics under Development by Companies 13
Chemotherapy Induced Neutropenia - Therapeutics under Investigation by Universities/Institutes 15
Chemotherapy Induced Neutropenia - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Chemotherapy Induced Neutropenia - Products under Development by Companies 20
Chemotherapy Induced Neutropenia - Products under Investigation by Universities/Institutes 22
Chemotherapy Induced Neutropenia - Companies Involved in Therapeutics Development 23
Apotex Inc. 23
Biogenomics Limited 24
Bolder Biotechnology, Inc. 25
Cellerant Therapeutics, Inc. 26
Chong Kun Dang Pharmaceutical Corp. 27
Cinfa Biotech S.L. 28
Dr. Reddy's Laboratories Limited 29
Generon (Shanghai) Corporation Ltd. 30
Genexine, Inc. 31
Hanmi Pharmaceuticals, Co. Ltd. 32
Myelo Therapeutics GmbH 33
Octapharma AG 34
Pfenex Inc. 35
Pfizer Inc. 36
PharmaEssentia Corporation 37
Reliance Life Sciences Pvt. Ltd. 38
Richter Gedeon Nyrt. 39
Sandoz International GmbH 40
UAB Profarma 41
USV Limited 42
Chemotherapy Induced Neutropenia - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Target 44
Assessment by Mechanism of Action 46
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
BBT-007 - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
BBT-015 - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
BBT-018 - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
EC-18 - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
eflapegrastim - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
F-627 - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
filgrastim - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
filgrastim - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
filgrastim - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
filgrastim - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
filgrastim - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
filgrastim - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
GW-003 - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
GXG-3 - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
HSA-GCSF - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
Myelo-001 - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
pegfilgrastim - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
pegfilgrastim - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
pegfilgrastim - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
pegfilgrastim - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
pegfilgrastim - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
pegfilgrastim - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
pegfilgrastim - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
pegfilgrastim - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
pegfilgrastim - Drug Profile 77
Product Description 77
Mechanism of Action 77
RandD Progress 77
pegfilgrastim - Drug Profile 78
Product Description 78
Mechanism of Action 78
RandD Progress 78
pegfilgrastim - Drug Profile 79
Product Description 79
Mechanism of Action 79
RandD Progress 79
pegfilgrastim - Drug Profile 80
Product Description 80
Mechanism of Action 80
RandD Progress 80
pegfilgrastim - Drug Profile 81
Product Description 81
Mechanism of Action 81
RandD Progress 81
romyelocel-L - Drug Profile 82
Product Description 82
Mechanism of Action 82
RandD Progress 82
TXA-302 - Drug Profile 83
Product Description 83
Mechanism of Action 83
RandD Progress 83
WBI-2100 - Drug Profile 85
Product Description 85
Mechanism of Action 85
RandD Progress 85
Chemotherapy Induced Neutropenia - Recent Pipeline Updates 86
Chemotherapy Induced Neutropenia - Dormant Projects 93
Chemotherapy Induced Neutropenia - Discontinued Products 95
Chemotherapy Induced Neutropenia - Product Development Milestones 96
Featured News and Press Releases 96
Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim 96
Dec 16, 2015: Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment for the Registrational Trial of SPI-2012, a Novel, Long Acting G-CSF in Patients with Breast Cancer 96
Dec 08, 2014: Generon Presents the Global Phase II Study Results for F-627 (benegrastim) at the American Society of Hematology 56th Annual Meeting at San Francisco 97
Sep 09, 2014: Spectrum Pharmaceuticals Makes Decision to Advance SPI-2012, a Novel Long-Acting GCSF, to Phase 3 Due to Positive Phase 2 Results in its Collaboration Program with Hanmi Pharm 99
May 28, 2014: Spectrum Pharmaceuticals Completes Enrollment in Phase 2 Trial of SPI-2012 - A Novel Long-Acting Granulocyte Colony Stimulating Factor to Treat Chemotherapy-induced Neutropenia 99
Apr 08, 2013: Spectrum Pharma Initiates Phase II Study Of Long-acting GCSF Drug Candidate SPI-2012 For Treatment Of Chemotherapy-induced Neutropenia 100
Jan 07, 2013: Generon Initiates Phase I/II Clinical Trial Of F-627 For Treatment Of Breast Cancer In China 100
May 10, 2011: Dr Reddy's Launches Pegfilgrastim In India Under Brand Name Peg-grafeel 101
Mar 22, 2011: Cellerant Initiates Phase I/II Clinical Trial Of CLT-008 For Chemotherapy Induced Neutropenia In Acute Leukemia Patients 101
Dec 08, 2010: Generon Presents Poster On F-627 At 52nd Annual Meeting Of American Society Of Hematology 102
Appendix 103
Methodology 103
Coverage 103
Secondary Research 103
Primary Research 103
Expert Panel Validation 103
Contact Us 103
Disclaimer 104

List of Tables
Number of Products under Development for Chemotherapy Induced Neutropenia, H1 2016 11
Number of Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Development, H1 2016 18
Comparative Analysis by Unknown Stage Development, H1 2016 19
Products under Development by Companies, H1 2016 20
Products under Development by Companies, H1 2016 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2016 22
Chemotherapy Induced Neutropenia - Pipeline by Apotex Inc., H1 2016 23
Chemotherapy Induced Neutropenia - Pipeline by Biogenomics Limited, H1 2016 24
Chemotherapy Induced Neutropenia - Pipeline by Bolder Biotechnology, Inc., H1 2016 25
Chemotherapy Induced Neutropenia - Pipeline by Cellerant Therapeutics, Inc., H1 2016 26
Chemotherapy Induced Neutropenia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 27
Chemotherapy Induced Neutropenia - Pipeline by Cinfa Biotech S.L., H1 2016 28
Chemotherapy Induced Neutropenia - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 29
Chemotherapy Induced Neutropenia - Pipeline by Generon (Shanghai) Corporation Ltd., H1 2016 30
Chemotherapy Induced Neutropenia - Pipeline by Genexine, Inc., H1 2016 31
Chemotherapy Induced Neutropenia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 32
Chemotherapy Induced Neutropenia - Pipeline by Myelo Therapeutics GmbH, H1 2016 33
Chemotherapy Induced Neutropenia - Pipeline by Octapharma AG, H1 2016 34
Chemotherapy Induced Neutropenia - Pipeline by Pfenex Inc., H1 2016 35
Chemotherapy Induced Neutropenia - Pipeline by Pfizer Inc., H1 2016 36
Chemotherapy Induced Neutropenia - Pipeline by PharmaEssentia Corporation, H1 2016 37
Chemotherapy Induced Neutropenia - Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2016 38
Chemotherapy Induced Neutropenia - Pipeline by Richter Gedeon Nyrt., H1 2016 39
Chemotherapy Induced Neutropenia - Pipeline by Sandoz International GmbH, H1 2016 40
Chemotherapy Induced Neutropenia - Pipeline by UAB Profarma, H1 2016 41
Chemotherapy Induced Neutropenia - Pipeline by USV Limited, H1 2016 42
Assessment by Monotherapy Products, H1 2016 43
Number of Products by Stage and Target, H1 2016 45
Number of Products by Stage and Mechanism of Action, H1 2016 47
Number of Products by Stage and Route of Administration, H1 2016 49
Number of Products by Stage and Molecule Type, H1 2016 51
Chemotherapy Induced Neutropenia Therapeutics - Recent Pipeline Updates, H1 2016 86
Chemotherapy Induced Neutropenia - Dormant Projects, H1 2016 93
Chemotherapy Induced Neutropenia - Dormant Projects (Contd..1), H1 2016 94
Chemotherapy Induced Neutropenia - Discontinued Products, H1 2016 95

List of Figures
Number of Products under Development for Chemotherapy Induced Neutropenia, H1 2016 11
Number of Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Products, H1 2016 18
Assessment by Monotherapy Products, H1 2016 43
Number of Products by Targets, H1 2016 44
Number of Products by Stage and Targets, H1 2016 44
Number of Products by Mechanism of Actions, H1 2016 46
Number of Products by Stage and Mechanism of Actions, H1 2016 46
Number of Products by Top 10 Routes of Administration, H1 2016 48
Number of Products by Stage and Routes of Administration, H1 2016 48
Number of Products by Molecule Types, H1 2016 50
Number of Products by Stage and Molecule Types, H1 2016 50

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

Ulcerative Colitis: Kol Insight

September 2016 $ 8085

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.